Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIDRIXNEO-LUNG in Resected NSCLC
NCT04078269Phase 1Completed
- Sponsor
- Ghent University Hospital
- Start
- Aug 2019
- Primary completion
- Feb 2024
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MIDRIXNEO-LUNG in non-small cell lung cancer (NSCLC), sponsored by Ghent University Hospital. Primary endpoint: Safety and tolerability of preparing and administrating the autologous dendritic cell-based vaccine. Started Aug 2019; status: completed.
02
Drugs
MIDRIXNEO-LUNG
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04078269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04078269.